IL6 and depressive disorder: Despite the prevailing psychiatric gestalt, based largely on studies examining TNF antagonists12,13,41, and contrary to our initial hypothesis, allogeneic HCT patients receiving the IL-6 antagonist tocilizumab experienced significantly worse—not better—depression, anxiety, pain, and sleep compared to HCT patients not receiving the drug.